25H-NBOMe
25H-NBOMe, also known as NBOMe-2C-H, is a derivative of the phenethylamine hallucinogen 2C-H, which acts as a highly potent full agonist for the human 5-HT2A receptor.
Use and effects
The active dose range of 25H-NBOMe in humans has not been reported and hence is unknown. This is in notable contrast to many other NBOMe drugs.Pharmacology
Pharmacodynamics
25H-NBOMe acts as an agonist of the serotonin 5-HT2 receptors.Its affinity for the serotonin 5-HT2A receptor was 133-fold higher than that of 2C-H and 24-fold higher than that of 25H-NB, whereas it was 4-fold lower than that of 2C-I and 64-fold lower than that of 25I-NBOMe. In terms of activational potency at the receptor, the drug's potency was 67-fold higher than that of 2C-H, whereas it was 6-fold lower than that of 2C-I and 35-fold lower than that of 25I-NBOMe. Hence, unlike other NBOMe drugs, 25H-NBOMe appears to have affinity and activational potency at the serotonin 5-HT2A receptor more in line with the 2C psychedelics like 2C-I and much lower than NBOMe drugs like 25I-NBOMe.
25H-NBOMe produces hyperlocomotion, a stimulant-like effect, and the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. Its potency in inducing the head-twitch response was variably lower than that of other NBOMe drugs like 25I-NBOMe and 25B-NBOMe. Conversely, its potency in inducing hyperlocomotion was about the same as that of 25I-NBOMe and 25C-NBOMe. The drug has also been found to produce antidepressant-like effects in rodents. 25H-NBOMe has shown reinforcing effects in rodents. This included conditioned place preference and self-administration.